Balance between activating NKG2D, DNAM-1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts

Immunology

Volumn 142, Issue 4, 2014, Pages 581-593

  Nielsen, Natasja ^a   Pascal, Veronique ^a   Fasth, Andreas E R ^b   Sundström, Yvonne ^b   Galsgaard, Elisabeth D ^a   Ahern, David ^c   Andersen, Martin ^a,d   Baslund, Bo ^e   Bartels, Else M ^d   Bliddal, Henning ^d,f   Feldmann, Marc ^c   Malmström, Vivianne ^b   Berg, Louise ^b   Spee, Pieter ^a   Söderström, Kalle ^a,c  

^a NOVO NORDISK A S   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Mental Health Center Glostrup   (Denmark)

^e University of Copenhagen   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CD94 NKG2A; Fibroblast like synoviocytes; Natural killer cytotoxicity; NKG2D

Indexed keywords

HLA E ANTIGEN; INTERLEUKIN 15; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR DNAM 1; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL INTERACTION; CELL MEDIATED CYTOTOXICITY; CELL MIGRATION; CELL SURVIVAL; DEGRANULATION; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDICINE; NATURAL KILLER CELL; NATURAL KILLER CELL NISHI; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLAST; SYNOVIAL FLUID; SYNOVIOCYTE; TISSUE STRUCTURE;

CD94/NKG2A; FIBROBLAST-LIKE SYNOVIOCYTES; NATURAL KILLER CYTOTOXICITY; NKG2D;

ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ARTHRITIS, RHEUMATOID; CELL DEGRANULATION; CELL LINE; FEMALE; FIBROBLASTS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; MALE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY D; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; SYNOVIAL MEMBRANE; UP-REGULATION;

EID: 84904048250     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12271     Document Type: Article

References (78)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365:2205-19.
2. Zvaifler NJ, Boyle D, Firestein GS. Early synovitis-synoviocytes and mononuclear cells. Semin Arthritis Rheum 1994; 23:11-6.
3. Muller-Ladner U, Kriegsmann J, Franklin BN et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996; 149:1607-15.
4. Niedermeier M, Pap T, Korb A. Therapeutic opportunities in fibroblasts in inflammatory arthritis. Best Pract Res Clin Rheumatol 2010; 24:527-40.
5. Pierer M, Rethage J, Seibl R et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 2004; 172:1256-65.
6. + T cell migration within synovial tissue. Arthritis Rheum 2003; 48:2472-82.
7. Nanki T, Nagasaka K, Hayashida K, Saita Y, Miyasaka N. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol 2001; 167:5381-5.
8. Rathanaswami P, Hachicha M, Sadick M, Schall TJ, McColl SR. Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J Biol Chem 1993; 268:5834-9.
9. Carrion M, Perez-Garcia S, Jimeno R et al. Inflammatory mediators alter interleukin-17 receptor, interleukin-12 and -23 expression in human osteoarthritic and rheumatoid arthritis synovial fibroblasts: immunomodulation by vasoactive intestinal peptide. NeuroImmunoModulation 2013; 20:274-84.
10. Gillgrass A, Ashkar A. Stimulating natural killer cells to protect against cancer: recent developments. Expert Rev Clin Immunol 2011; 7:367-82.
11. Sun JC, Beilke JN, Bezman NA, Lanier LL. Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection. J Exp Med 2011; 208:357-68.
12. Bhat R, Rommelaere J. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells. BMC Cancer 2013; 13:367.
13. Dayanc BE, Bansal S, Gure AO, Gollnick SO, Repasky EA. Enhanced sensitivity of colon tumour cells to natural killer cell cytotoxicity after mild thermal stress is regulated through HSF1-mediated expression of MICA. Int J Hyperthermia 2013; 29:480-90.
14. Soderstrom K, Stein E, Colmenero P et al. Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci U S A 2010; 107:13028-33.
15. Fernandez NC, Lozier A, Flament C et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5:405-11.
16. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002; 195:327-33.
17. Morandi B, Bougras G, Muller WA, Ferlazzo G, Munz C. NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN-γ secretion. Eur J Immunol 2006; 36:2394-400.
18. + T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. Immunity 2007; 26:593-604.
19. Leavenworth JW, Wang X, Wenander CS, Spee P, Cantor H. Mobilization of natural killer cells inhibits development of collagen-induced arthritis. Proc Natl Acad Sci U S A 2011; 108:14584-9.
20. + regulatory T cells: interruption of the NKG2A-Qa-1 interaction allows robust suppressive activity and resolution of autoimmune disease. Proc Natl Acad Sci U S A 2008; 105:19420-5.
21. 2. Proc Natl Acad Sci U S A 2010; 107:2562-7.
22. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986; 136:4480-6.
23. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989; 143:3183-91.
24. bright immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer. Thyroid 2013; 23:1561-8.
25. bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003; 101:3052-7.
26. Ferlazzo G, Munz C. NK cell compartments and their activation by dendritic cells. J Immunol 2004; 172:1333-9.
27. - NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol 2006; 36:118-28.
28. - cells and display an impaired capability to kill tumor cells. Cancer 2008; 112:863-75.
29. de Matos CT, Berg L, Michaelsson J, Fellander-Tsai L, Karre K, Soderstrom K. Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: role of CD94/NKG2A in control of cytokine secretion. Immunology 2007; 122:291-301.
30. - phenotype. Rheumatology (Oxford) 2003; 42:870-8.
31. Chan A, Filer A, Parsonage G et al. Mediation of the proinflammatory cytokine response in rheumatoid arthritis and spondylarthritis by interactions between fibroblast-like synoviocytes and natural killer cells. Arthritis Rheum 2008; 58:707-17.
32. Schrambach S, Ardizzone M, Leymarie V, Sibilia J, Bahram S. In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer. PLoS ONE 2007; 2:e518.
33. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci U S A 2003; 100:9452-7.
34. Nozaki T, Takahashi K, Ishii O et al. Development of an ex vivo cellular model of rheumatoid arthritis: critical role of CD14-positive monocyte/macrophages in the development of pannus tissue. Arthritis Rheum 2007; 56:2875-85.
35. Qu Z, Huang XN, Ahmadi P et al. Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. Lab Invest 1995; 73:339-46.
36. Cerboni C, Mousavi-Jazi M, Wakiguchi H, Carbone E, Karre K, Soderstrom K. Synergistic effect of IFN-γ and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity. Eur J Immunol 2001; 31:2926-35.
37. Iwanaga T, Shikichi M, Kitamura H, Yanase H, Nozawa-Inoue K. Morphology and functional roles of synoviocytes in the joint. Arch Histol Cytol 2000; 63:17-31.
38. Palmer DG, Selvendran Y, Allen C, Revell PA, Hogg N. Features of synovial membrane identified with monoclonal antibodies. Clin Exp Immunol 1985; 59:529-38.
39. Stevens CR, Mapp PI, Revell PA. A monoclonal antibody (Mab 67) marks type B synoviocytes. Rheumatol Int 1990; 10:103-6.
40. Helander TS, Timonen T. Adhesion in NK cell function. Curr Top Microbiol Immunol 1998; 230:89-99.
41. Jung H, Hsiung B, Pestal K, Procyk E, Raulet DH. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J Exp Med 2012; 209:2409-22.
42. Cantoni C, Bottino C, Vitale M et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 1999; 189:787-96.
43. Kulkarni GV, McCulloch CA. Serum deprivation induces apoptotic cell death in a subset of BALB/c 3T3 fibroblasts. J Cell Sci 1994; 107(Pt 5):1169-79.
44. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294:15-22.
45. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23:225-74.
46. McInnes IB, al-Mughales J, Field M et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 1996; 2:175-82.
47. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997; 3:189-95.
48. Schulz U, Kreutz M, Multhoff G et al. Interleukin-10 promotes NK cell killing of autologous macrophages by stimulating expression of NKG2D ligands. Scand J Immunol 2010; 72:319-31.
49. El-Sherbiny YM, Meade JL, Holmes TD et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 2007; 67:8444-9.
50. Lunemann A, Lunemann JD, Roberts S et al. Human NK cells kill resting but not activated microglia via NKG2D- and NKp46-mediated recognition. J Immunol 2008; 181:6170-7.
51. Magri G, Muntasell A, Romo N et al. NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies. Blood 2011; 117:848-56.
52. Andresen L, Hansen KA, Jensen H et al. Propionic acid secreted from propionibacteria induces NKG2D ligand expression on human-activated T lymphocytes and cancer cells. J Immunol 2009; 183:897-906.
53. Vales-Gomez M, Chisholm SE, Cassady-Cain RL, Roda-Navarro P, Reyburn HT. Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res 2008; 68:1546-54.
54. Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, Santoni A. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis. Blood 2007; 110:606-15.
55. Molinero LL, Domaica CI, Fuertes MB, Girart MV, Rossi LE, Zwirner NW. Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity. Hum Immunol 2006; 67:170-82.
56. + T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A. PLoS ONE 2012; 7:e31959.
57. Roy S, Barnes PF, Garg A, Wu S, Cosman D, Vankayalapati R. NK cells lyse T regulatory cells that expand in response to an intracellular pathogen. J Immunol 2008; 180:1729-36.
58. Mandelboim O, Lieberman N, Lev M et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001; 409:1055-60.
59. Baychelier F, Sennepin A, Ermonval M, Dorgham K, Debre P, Vieillard V. Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood 2013; 122:2935-42.
60. Bottino C, Castriconi R, Moretta L, Moretta A. Cellular ligands of activating NK receptors. Trends Immunol 2005; 26:221-6.
61. Kurowska M, Rudnicka W, Kontny E et al. Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2. J Immunol 2002; 169:1760-7.
62. + T lymphocytes in the adaptive immune response to pathogens and tumors. J Biomed Biotechnol 2010; 2010:907092.
63. Brooks AG, Borrego F, Posch PE et al. Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells. J Immunol 1999; 162:305-13.
64. dim NK cells. Eur J Immunol 2001; 31:3121-7.
65. dim+ lymphokine-activated killer cells. J Immunol 1989; 142:2949-54.
66. Tak PP, Kummer JA, Hack CE et al. Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum 1994; 37:1735-43.
67. bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol 2004; 173:6418-26.
68. + T-cells in sarcoidosis patients. Eur Respir J 2005; 26:77-85.
69. bright cells in tuberculous pleurisy. J Immunol 2005; 175:6852-60.
70. Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-β. Neurol Sci 2007; 28:121-6.
71. + Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol 2009; 215:125-8.
72. Wiendl H, Gross CC. Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol 2013; 9:394-404.
73. Smith MD. The normal synovium. Open Rheumatol J 2011; 5:100-6.
74. Harlin H, Hanson M, Johansson CC et al. J Immunol 2007; 179:4513-9.
75. bright subset of NK cells is resistant to oxidant-induced cell death. J Immunol 2007; 179:781-5.
76. Harada S, Yamamura M, Okamoto H et al. Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 1999; 42:1508-16.
77. Miranda-Carus ME, Balsa A, Benito-Miguel M, de Perez AC, Martin-Mola E. IL-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: effect of methotrexate. J Immunol 2004; 173:1463-76.
78. Zwirner NW, Domaica CI. Cytokine regulation of natural killer cell effector functions. BioFactors 2010; 36:274-88.